Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation

Abstract

Among patients with advanced breast cancer and a germline BRCA1/2 mutation, single-agent talazoparib provided a significant benefit over standard chemotherapy with respect to progression-free survival. Patient-reported outcomes were superior with talazoparib. (Funded by Medivation [Pfizer]; EMBRACA ClinicalTrials.gov number, NCT01945775 .).

Keywords

Affiliated Institutions

• Pfizer (United States) US
• UCSF Helen Diller Family Comprehensive Cancer Center US
• University of California, Los Angeles US
• Rabin Medical Center IL
• Texas Oncology US
• GEICAM – Spanish Breast Cancer Group ES
• Centro de Investigación Biomédica en Red de Cáncer ES
• Institut Claudius Regaud FR
• The University of Texas MD Anderson Cancer Center US
• Institut Paoli-Calmettes FR
• University of California, San Francisco US
• Samsung Medical Center KR
• Technical University of Munich DE
• Seoul National University Hospital KR
• Kaiser Permanente Vallejo Medical Center US
• The US Oncology Network US
• Klinikum rechts der Isar DE

Related Publications